{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-005894","form_type":"8-K","ticker":"AIM","cik":"0000946644","company_name":"AIM ImmunoTech Inc.","filed_at":"2022-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.497317+00:00","generated_at":"2026-06-27T02:15:04.197679+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AIM ImmunoTech appoints Robert Dickey IV as CFO; Lintal transitions to consultant","bullets":["Robert Dickey IV becomes CFO effective April 4, 2022, replacing Ellen Lintal who moves to consultant role.","Dickey compensated $375/hour under a one-year consulting agreement with his firm Foresite Advisors.","Dickey brings 25+ years of life science CFO and investment banking experience, including 18 years at Lehman Brothers.","He previously served as senior vice president of AIM from 2008 to 2013.","Press release issued March 3, 2022; contract terminable on 60-day notice (non-cause) or 30-day (cause)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-005894","json":"https://secwatch.observer/filing/0001493152-22-005894.json","markdown":"https://secwatch.observer/filing/0001493152-22-005894.md","text":"https://secwatch.observer/filing/0001493152-22-005894.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946644/000149315222005894/0001493152-22-005894-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946644/000149315222005894/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T02:15:04.197679+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8975c8783e","claim":"Ellen Lintal departed as Chief Financial Officer at AIM ImmunoTech Inc..","evidence_excerpt":"On March 1, 2022, the Company entered into a consulting agreement with Ellen Lintal, who will step down as the Company’s Chief Financial Officer on April 4, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315222005894/0001493152-22-005894-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"af44f39c35","claim":"Robert Dickey IV was appointed as Chief Financial Officer at AIM ImmunoTech Inc..","evidence_excerpt":"On March 1, 2022, after review and approval by the Board of Directors, the Company entered into a consulting agreement with Foresite Advisors, LLC, a company wholly-owned by Robert Dickey IV, pursuant to which Mr. Dickey will serve as the Company’s new Chief Financial Officer effective April 4, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315222005894/0001493152-22-005894-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}